INS and type 2 diabetes mellitus: The incretin, glucagon-like peptide 1 (GLP-1), secreted after meal ingestion from L-cells found primarily in the distal intestine [1], promotes the secretion of insulin and somatostatin by pancreatic beta- and delta- cells, respectively, and decreases glucagon production from alpha-cells, as well as appetite and gastric emptying Together with a suggested action on beta-cell proliferation [2], and an absence of adverse effects such as weight gain and hypoglycaemic episodes [3], GLP-1 is an ideal candidate as a drug to treat type 2 diabetes (T2D)[4].